Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: sucrose; water for injections; monobasic sodium phosphate; poloxamer; nitrogen; dibasic sodium phosphate - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: poloxamer; nitrogen; sucrose; dibasic sodium phosphate; monobasic sodium phosphate; water for injections - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; crospovidone; sodium stearylfumarate; povidone; lactose - hypertension: monopril is indicated in the treatment of mild to moderate hypertension. monopril is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of monopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of monopril in severe or renovascular hypertension. heart failure: monopril is indicated for the management of heart failure when added to conventional therapy, including diuretics.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - saxagliptin; metformin hydrochloride -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - stavudine -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - stavudine -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - dicloxacillin sodium -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - dicloxacillin sodium -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - dicloxacillin sodium -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - stavudine -